2020
Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors
Coleman EL, Olamiju B, Leventhal JS. Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors. Oncology Reports 2020, 45: 891-898. PMID: 33650659, PMCID: PMC7859912, DOI: 10.3892/or.2020.7911.Peer-Reviewed Original ResearchConceptsSevere cutaneous adverse reactionsTyrosine kinase inhibitorsLife-threatening severe cutaneous adverse reactionsAcute generalized exanthematous pustulosisEpidermal growth factor receptorStevens-Johnson syndromeCutaneous adverse reactionsToxic epidermal necrolysisVascular endothelial growth factorGrowth factor receptorAnaplastic lymphoma kinasePlatelet-derived growth factorAdverse reactionsFibroblast growth factor receptorFactor receptorApplication of TKIsGrowth factorHuman epidermal growth factor receptorKinase inhibitorsGeneralized exanthematous pustulosisPotential cutaneous toxicityEndothelial growth factorExanthematous pustulosisEpidermal necrolysisCutaneous toxicityCutaneous immune-related adverse events to checkpoint inhibitors
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.Peer-Reviewed Original ResearchConceptsAdverse reactionsCheckpoint inhibitorsImmune-related adverse reactionsCheckpoint inhibitor therapyCutaneous adverse eventsOngoing cancer treatmentPD-1 inhibitorsCTLA-4 inhibitorsImmune checkpoint inhibitorsCutaneous adverse reactionsPD-L1 inhibitorsDevelopment of immunotherapySuch adverse reactionsImmunomodulatory therapyTreatment interruptionAssociated morbidityPatient comorbiditiesAdverse eventsCutaneous toxicityInhibitor therapyImmune statusHematologic malignanciesEarly recognitionCancer treatmentManagement guidelines
2012
Hypersensitivity Reactions to Vaccine Constituents
Leventhal JS, Berger EM, Brauer JA, Cohen DE. Hypersensitivity Reactions to Vaccine Constituents. Dermatitis 2012, 23: 102-109. PMID: 22653170, DOI: 10.1097/der.0b013e31825228cf.Peer-Reviewed Original ResearchConceptsHypersensitivity reactionsCutaneous delayed-type hypersensitivityDelayed-type hypersensitivity reactionDelayed-type hypersensitivityChoice of vaccineElicit adverse reactionsComponents of vaccinesClinical manifestationsVaccine safetyAdverse reactionsVaccine constituentsCommon vaccinesDrug AdministrationSusceptible individualsVaccineHypersensitivityPatientsAdjuvantPhysiciansAdministrationThimerosal